Supplementary materials: Cost–effectiveness analysis of prolonged-release fampridine to treat walking disability of multiple sclerosis in China

<b>These are peer-reviewed supplementary materials for the article '</b><b>Cost–effectiveness analysis of </b><b>prolonged-release fampridine to treat </b><b>walking disability of multiple sclerosis in </b><b>China</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Symptomatic medications and duration of treatment in multiple sclerosis (MS) adult patients with walking disability (EDSS [expanded disability status scale] score 4-7)</b><b>Frequency and duration of rehabilitation therapy in MS adult patients with walking disability (EDSS score 4-7)</b><b>Healthcare resource utilization in the treatment of MS adult patients with walking disability (EDSS score 4-7)</b><b>The relationship between walking ability and costs</b><b>Supplementary Table 1 EQ-5D-5L utilities from the ENHANCE and MOBILE trial</b><b>Objectives: </b>This study evaluates the cost–effectiveness of adding prolonged-release (PR)-fampridine to best supportive care (BSC) versus BSC alone in adult multiple sclerosis patients with walking disability in China. <b>Materials &amp; methods:</b> A hybrid decision tree and Markov model from both the societal and healthcare perspectives were constructed. Parameters were derived from clinical trials of PR-fampridine, published sources and clinical expert interviews. <b>Results: </b>Over a 10-year time horizon, adding PRfampridine to BSC led to 0.15 quality-adjusted life year (QALY) gain and lower costs,with incremental cost–effectiveness ratios of -238,806 Chinese Yuan/QALY and -113,488 Chinese Yuan/QALY from the societal and healthcare perspectives, respectively. <b>Conclusion:</b> Compared with BSC alone, PR-fampridine plus BSC is considered an economically dominant strategy for the treatment of multiple sclerosis-related walking disability in China.

本数据集为发表于《比较疗效研究期刊》（*Journal of Comparative Effectiveness Research*）的论文《中国多发性硬化症步行障碍患者使用缓释型达伐吡啶的成本效用分析》的同行评议补充材料。
伴步行障碍（扩展残疾状态量表（Expanded Disability Status Scale, EDSS）评分4-7分）的成年多发性硬化症（Multiple Sclerosis, MS）患者的对症用药与治疗时长
伴步行障碍（EDSS评分4-7分）的成年MS患者的康复治疗频次与时长
伴步行障碍的成年MS患者治疗期间的医疗资源利用情况
步行能力与医疗成本的关联
补充表1：ENHANCE与MOBILE试验中的EQ-5D-5L效用值
研究目标：本研究旨在评估在中国人群中，针对伴步行障碍的成年多发性硬化症患者，在最佳支持治疗（Best Supportive Care, BSC）基础上加用缓释型达伐吡啶，与单纯采用最佳支持治疗的成本效用对比。
材料与方法：本研究从社会层面与医疗保障层面构建混合决策树-马尔可夫模型，模型参数源自缓释型达伐吡啶的临床试验、已发表文献及临床专家访谈。
研究结果：在10年的研究周期内，在最佳支持治疗基础上加用缓释型达伐吡啶可带来0.15个质量调整生命年（Quality-Adjusted Life Year, QALY）的获益，同时降低医疗成本；从社会层面与医疗保障层面计算的增量成本效用比分别为-238806元/QALY与-113488元/QALY。
研究结论：相较于单纯最佳支持治疗，在中国人群中，缓释型达伐吡啶联合最佳支持治疗被视为治疗多发性硬化症相关步行障碍的经济优势策略。